TY - JOUR
T1 - Weight gain and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
AU - the Hereditary Ovarian Cancer Clinical Study Group
AU - Kim, Shana J.
AU - Lubinski, Jan
AU - Huzarski, Tomasz
AU - Møller, Pål
AU - Armel, Susan
AU - Karlan, Beth Y.
AU - Senter, Leigha
AU - Eisen, Andrea
AU - Foulkes, William D.
AU - Singer, Christian F.
AU - Tung, Nadine
AU - Bordeleau, Louise
AU - Neuhausen, Susan L.
AU - Olopade, Olufunmilayo I.
AU - Eng, Charis
AU - Weitzel, Jeffrey N.
AU - Fruscio, Robert
AU - Narod, Steven A.
AU - Kotsopoulos, Joanne
AU - Gronwald, Jacek
AU - Cybulski, Cezary
AU - Pal, Tuya
AU - Wiesner, Georgia
AU - Rosen, Barry
AU - McCuaig, Jeanna
AU - Kim, Raymond
AU - Demsky, Rochelle
AU - Sweet, Kevin
AU - Zakalik, Dana
AU - Wood, Marie
AU - McKinnon, Wendy
AU - Elser, Christine
AU - Wiesner, Georgia
AU - Friedman, Eitan
AU - Meschino, Wendy
AU - Snyder, Carrie
AU - Metcalfe, Kelly
AU - Poll, Aletta
AU - Warner, Ellen
AU - Ainsworth, Peter
AU - Steele, Linda
AU - Saal, Howard
AU - Serfas, Kim
AU - Panchal, Seema
AU - Cullinane, Carey A.
AU - Reilly, Robert E.
AU - Blum, Joanne L.
AU - Kwong, Ava
AU - Rayson, Daniel
AU - Isaacs, Claudine
AU - Cajal, Teresa Ramón
AU - Dungan, Jeffrey
AU - Yerushalmi, Rinat
AU - Ginsburg, Ophira
AU - Sun, Sophie
AU - Schraeder, Intan
AU - Cohen, Stephanie
AU - Lemire, Edmond
AU - Zovato, Stefania
AU - Rastelli, Antonella
AU - MacDougall, Ellen
AU - Ngwa, Clotilde
AU - Kundu, Anasua
AU - Nahar, Nurun
AU - Sims, Abigail
AU - Parco, Alexandra
AU - Zhu, Christine
AU - Zhang, Cindy
AU - Hall, Elizabeth
AU - Asbroek, Lisa
AU - Raj, Rebecca
AU - Laurie, Shaelyn
AU - Urmi, Kamrun
AU - Mahmood, Amina
AU - Gholizadeh, Mayra
AU - Awan, Nazia
AU - Dehal, Neelam
AU - Chaudhary, Pooja
AU - Patel, Pooja
AU - Syeda, Aiman
AU - Tehrani, Yasmin
AU - Venkatewsaran, Seetha
AU - Krishnapillai, Suvetha
AU - Mdou, Elvis
AU - Mehta, Seema
AU - Brar, Jasdeep
AU - Supriadi, Marsela
AU - Patel, Bhumi
AU - Mahmoodi, Fabiah
AU - Zhaung, Jie
AU - Trister, Rachel
N1 - Funding Information:
This work was supported by the Canadian Institutes of Health Research (FDN 154275); Canadian Cancer Society Research Institute (703058); and the Peter Gilgan Center for Women's Cancers at Women's College Hospital in partnership with the Canadian Cancer Society. Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair. Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible.
Funding Information:
L. Senter reports other from AstraZeneca outside the submitted work. W.D. Foulkes reports grants from AstraZeneca outside the submitted work. C.F. Singer reports grants and personal fees from Novartis; grants, personal fees, and non-financial support from Roche and AstraZeneca; and grants and non-financial support from Amgen during the conduct of the study. O.I. Olopade reports other from CancerIQ, Tempus, and 54gene outside the submitted work. J.N. Weitzel reports personal fees from AstraZeneca outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
This work was supported by the Canadian Institutes of Health Research (FDN 154275); Canadian Cancer Society Research Institute (703058); and the Peter Gilgan Center for Women’s Cancers at Women’s College Hospital in partnership with the Canadian Cancer Society. Joanne Kotsopoulos is a recipient of a Tier II Canada Research Chair. Steven A. Narod is the recipient of a Tier I Canada Research Chair. Our sincere gratitude for the valuable contributions of the women who participated in this study, without whom this research would not be possible. We would like to acknowledge the other members of the Hereditary Ovarian Cancer Clinical Study Group: Jacek Gronwald, Cezary Cybulski, Tuya Pal, Georgia Wiesner, Barry Rosen, Jeanna McCuaig, Raymond Kim, Rochelle Demsky, Kevin Sweet, Dana Zakalik, Marie Wood, Wendy McKinnon, Christine Elser, Georgia Wiesner, Eitan Friedman, Wendy
Publisher Copyright:
© 2021 American Association for Cancer Research
PY - 2021/11
Y1 - 2021/11
N2 - Background: Weight gain and other anthropometric measures on the risk of ovarian cancer for women with BRCA mutations are not known. We conducted a prospective analysis of weight change since age 18, height, body mass index (BMI) at age 18, and current BMI and the risk of developing ovarian cancer among BRCA1 and BRCA2 mutation carriers. Methods: In this prospective cohort study, height, weight, and weight at age 18 were collected at study enrollment. Weight was updated biennially. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for ovarian cancer. Results: This study followed 4,340 women prospectively. There were 121 incident cases of ovarian cancer. Weight gain of more than 20 kg since age 18 was associated with a 2-fold increased risk of ovarian cancer, compared with women who maintained a stable weight (HR, 2.00; 95% CI, 1.13-3.54; P ¼ 0.02). Current BMI of 26.5 kg/m2 or greater was associated with an increased risk of ovarian cancer in BRCA1 mutation carriers, compared with those with a BMI less than 20.8 kg/m2 (Q4 vs. Q1 HR, 2.13; 95% CI, 1.04-4.36; P ¼ 0.04). There were no significant associations between height or BMI at age 18 and risk of ovarian cancer. Conclusions: Adult weight gain is a risk factor for ovarian cancer in women with a BRCA1 or BRCA2 mutation. Impact: These findings emphasize the importance of maintaining a healthy body weight throughout adulthood in women at high risk for ovarian cancer.
AB - Background: Weight gain and other anthropometric measures on the risk of ovarian cancer for women with BRCA mutations are not known. We conducted a prospective analysis of weight change since age 18, height, body mass index (BMI) at age 18, and current BMI and the risk of developing ovarian cancer among BRCA1 and BRCA2 mutation carriers. Methods: In this prospective cohort study, height, weight, and weight at age 18 were collected at study enrollment. Weight was updated biennially. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for ovarian cancer. Results: This study followed 4,340 women prospectively. There were 121 incident cases of ovarian cancer. Weight gain of more than 20 kg since age 18 was associated with a 2-fold increased risk of ovarian cancer, compared with women who maintained a stable weight (HR, 2.00; 95% CI, 1.13-3.54; P ¼ 0.02). Current BMI of 26.5 kg/m2 or greater was associated with an increased risk of ovarian cancer in BRCA1 mutation carriers, compared with those with a BMI less than 20.8 kg/m2 (Q4 vs. Q1 HR, 2.13; 95% CI, 1.04-4.36; P ¼ 0.04). There were no significant associations between height or BMI at age 18 and risk of ovarian cancer. Conclusions: Adult weight gain is a risk factor for ovarian cancer in women with a BRCA1 or BRCA2 mutation. Impact: These findings emphasize the importance of maintaining a healthy body weight throughout adulthood in women at high risk for ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85119001862&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0296
DO - 10.1158/1055-9965.EPI-21-0296
M3 - Article
C2 - 34426412
AN - SCOPUS:85119001862
SN - 1055-9965
VL - 30
SP - 2038
EP - 2043
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 11
ER -